Open AccessFirst successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
Author(s) -
Omura Minami,
Kosaka Takeo,
Aimono Eriko,
Nakamura Kohei,
Hongo Hiroshi,
Mikami Shuji,
Nishihara Hiroshi,
Oya Mototsugu
Publication year - 2022
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12383
Subject(s) - pten , prostate cancer , medicine , oncology , chemotherapy , dna damage repair , prostate , cancer , cancer research , bioinformatics , pi3k/akt/mtor pathway , gene , biology , dna repair , apoptosis , genetics
Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation We report the case of a Japanese patient with advanced castration‐resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.